Evidence map›Paper›PMID 29959603›Full record

ArticlePharmaceutical research2018

Naïve Bayesian Models for Vero Cell Cytotoxicity.

Alexander L Perryman, Jimmy S Patel, Riccardo Russo, Eric Singleton, Nancy Connell, Sean Ekins, Joel S Freundlich

Abstract read
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. ACS infectious diseases · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Random Forest Model Prediction of Compound Oral Exposure in the Mouse.ACS pharmacology & translational science · 2021
    Article
  13. Article
  14. A review on machine learning approaches and trends in drug discovery.Computational and structural biotechnology journal · 2021
    Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander L PerrymanDepartment of Pharmacology, Physiology and Neuroscience, and Medicine, Rutgers University-New Jersey Medical School, Medical Sciences Building, I-503, 185 South Orange Ave, Newark, NJ, 07103, USA.
Jimmy S PatelDepartment of Pharmacology, Physiology and Neuroscience, and Medicine, Rutgers University-New Jersey Medical School, Medical Sciences Building, I-503, 185 South Orange Ave, Newark, NJ, 07103, USA.
Riccardo RussoDivision of Infectious Diseases, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Medical Sciences Building, I-503, 185 South Orange Ave, Newark, NJ, 07103, USA.
Eric SingletonDivision of Infectious Diseases, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Medical Sciences Building, I-503, 185 South Orange Ave, Newark, NJ, 07103, USA.
Nancy ConnellDivision of Infectious Diseases, Department of Medicine, and the Ruy V. Lourenço Center for the Study of Emerging and Re-emerging Pathogens, Rutgers University-New Jersey Medical School, Medical Sciences Building, I-503, 185 South Orange Ave, Newark, NJ, 07103, USA.
Sean EkinsCollaborations Pharmaceuticals, Inc., Main Campus Drive Lab 3510, Raleigh, North Carolina,, 27606, USA.
Joel S FreundlichDepartment of Pharmacology, Physiology and Neuroscience, and Medicine, Rutgers University-New Jersey Medical School, Medical Sciences Building, I-503, 185 South Orange Ave, Newark, NJ, 07103, USA. freundjs@rutgers.edu.ORCID http://orcid.org/0000-0002-3411-3455

Funding

Therapeutics for drug resistant-bacteria: Arylpropionyl-phloroglucinolsU19AI109713 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI PERLIN, DAVID S · 2014 to 2018
$26.9M
NIAID NIH HHS U19 AI109713NIH HHS U19AI109713
6 · The paper itself

Abstract

purposeTo advance translational research of potential therapeutic small molecules against infectious microbes, the compounds must display a relative lack of mammalian cell cytotoxicity. Vero cell cytotoxicity (CC

methodsVero cell cytotoxicity assays were identified in PubChem, reformatted, and curated to create a training set with 8741 unique small molecules. These data were used to develop Bayesian classifiers, which were assessed with internal cross-validation, external tests with a set of 193 compounds from our laboratory, and independent validation with an additional diverse set of 1609 unique compounds from PubChem.

resultsEvaluation with independent, external test and validation sets indicated that cytotoxicity Bayesian models constructed with the ECFP_6 descriptor were more accurate than those that used FCFP_6 fingerprints. The best cytotoxicity Bayesian model displayed predictive power in external evaluations, according to conventional and chance-corrected statistics, as well as enrichment factors.

conclusionsThe results from external tests demonstrate that our novel cytotoxicity Bayesian model displays sufficient predictive power to help guide translational research. To assist the chemical tool and drug discovery communities, our curated training set is being distributed as part of the Supplementary Material. Graphical Abstract Naive Bayesian models have been trained with publically available data and offer a useful tool for chemical biology and drug discovery to select for small molecules with a high probability of exhibiting acceptably low Vero cell cytotoxicity.

Indexed as

Bayes TheoremModels, BiologicalAnimalsChlorocebus aethiopsDatabases, PharmaceuticalDrug DiscoveryInformation Storage and RetrievalModels, MolecularSmall Molecule LibrariesToxicity TestsVero CellsSmall Molecule LibrariesBayesian modelmachine learningpredicting mammalian cytotoxicitytranslational researchvero cell CC50

Identifiers

PMID29959603
PMCPMC7768703

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.